Circulating Epstein–Barr virus DNA as a precision biomarker in nasopharyngeal carcinoma: from risk stratification to real-time treatment adaptation and disease surveillance
EBV DNA is evolving from a static biomarker into an operational tool for precision oncology in NPC. Its integration enables biologically informed risk stratification, dynamic response assessment, and adaptive treatment strategies, with important implications for personalized management of NPC.
Authors
- Jia Ling Neo
- Emma R.Y. Zhang
- Melvin L.K. Chua
Institutions
- University of California, Los Angeles (US)
- Duke-NUS Medical School (SG)
- National Cancer Centre Singapore (SG)
Publication Details
- Journal
- Current Opinion in Oncology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1097/cco.0000000000001231
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00